Peter Hillmen P, Badoux X, Delgado J, et al. Safety results of terminated phase 2 study of idelalisib plus rituximab in treatment naïve chronic lymphocytic leukemia (CLL) with del(17p). EHA 2017, abstract S465.
Lisocabtagene maraleucel bij gerecidiveerd of refractair B-cellymfoom
sep 2020 | Lymfoom